The Patent Finder
CA

CureVac AG

First filing 2003
OverviewNotableFeesChangesFamiliesPatent listSources & methods

131 patents currently held

15 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Oct 2028. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
3
Ending by 2030
Oct 2028
Next term end
58
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Combination of Vaccination and Inhibition of the PD-1 Pathway US 9,974,845
Cited by 177 later US patents, top 1% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
Ends Sep 2034 · High confidence
Also notable
Artificial Nucleic Acid Molecules for Improved Protein Expression US 11,149,278
Cited by 139 later US patents, top 1% of utility patents granted in 2021 in our data. Protection runs to 2036.
Ends Feb 2036 · High confidence
Also notable
Coronavirus Vaccine US 11,576,966
Cited by 26 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2041.
Ends Feb 2041 · High confidence

Formerly held, still cited

Notable
Cited by 101 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2036.
Ends Jul 2036 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 3 fees due Dec 4 to 27, 2026 · next Dec 4
  • 3 fees due Jan 4 to 11, 2027 · next Jan 4
  • 3 fees due Feb 6 to 28, 2027 · next Feb 6
  • 1 fee due Mar 19, 2027
    The maintenance fee for Artificial Nucleic Acid Molecules for Improved Protein Expression (US 11,761,009) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.
  • 4 fees due Apr 8 to 17, 2027 · next Apr 8
  • 1 fee due Jun 30, 2027
    The maintenance fee for Dry Powder Composition Comprising Long-Chain RNA (US 10,517,827) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
  • 3 fees due Jul 5 to 12, 2027 · next Jul 5
  • 3 fees due Sep 5 to 24, 2027 · next Sep 5
  • 4 fees due Oct 7 to 23, 2027 · next Oct 7
  • 1 fee due Nov 7, 2027
    The maintenance fee for VACCINATION WITH mRNA-CODED ANTIGENS (US 11,975,064) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 23, 2026
  • 1 term has ended since Aug 23, 2026

What they patent

The largest of its 58 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 10,434,154Composition for Treating Prostate Cancer (PCa)
In force
 · High confidence
In forceHigh confidence
US 11,421,038RNA-Coded Antibody
In force
 · High confidence
In forceHigh confidence
US 10,441,653Nucleic Acid Comprising GlXmGn as an Immune-Stimulating Agent/Adjuvant
In force
 · Medium confidence
In forceMedium confidence
US 8,968,746Complexation of Nucleic Acids with Disulfide-Crosslinked Cationic Components for Transfection and Immunostimulation
In force
 · High confidence
In forceHigh confidence
US 9,234,013Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Protein
In force
 · High confidence
In forceHigh confidence
US 9,839,697Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Protein
In force
 · Medium confidence
In forceMedium confidence
US 10,010,592Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Tumour Antigen
In force
 · Medium confidence
In forceMedium confidence
US 10,232,024Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Allergenic Antigen or an Autoimmune Self-Antigen
In force
 · Medium confidence
In forceMedium confidence
US 10,653,799Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Protein
In force
 · Medium confidence
In forceMedium confidence
US 11,110,156Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Tumour Antigen
In force
 · High confidence
In forceHigh confidence
10 of 131 patents shown.
Pro members see all 131.
Pro members: see all 131 patents
Also on record, not counted in the 131: 15 patents in force now held by others · 31 patents ended · 87 applications pending · 137 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited